<DOC>
	<DOCNO>NCT02176681</DOCNO>
	<brief_summary>Diabetes major concern dialysis unit , common cause end-stage renal disease France . In 2010 initiation dialysis treatment , one patient two least one cardiovascular disease 40 % diabetes ( 94 % Type 2 diabetes ) especially East part France . Diabetic patient dialysis high burden morbidity mortality , particularly cardiovascular disease . Tight glycaemic blood pressure control diabetic patient important impact reduce risk progression nephropathy . Data scarce diabetes best treat dialysis patient . The evidence improve glycaemic control patient dialysis impact mortality morbidity sparse . Indeed , many factor make improve glycaemic control patient dialysis challenging , include therapeutic difficulty hypoglycaemic agent , monitor difficulty , dialysis strategy exacerbate hyperglycaemia hypoglycaemia . Standard oral drug therapy hyperglycaemia ( eg , metformin , sulfonylureas , ) contraindicate patient dialysis . Thus insulin mainstay treatment . Newer therapy hyperglycaemia , gliptins glucagon-like peptide-1 analogue become available , recently , renal failure preclude use . Newer gliptins , however , license use 'severe renal failure ' , although yet trialed dialysis patient . The investigator study , use continuous glucose monitor new tool monitoring therapy provide information vildagliptin add therapy insulin population .</brief_summary>
	<brief_title>A Prospective , Multicenter , Randomized , Open-label Study 12 Week Duration Evaluate Effect VILDagliptin Added Insulin Glycaemic Control haemoDIALyzed Patients With Type 2 Diabetes : Probe Analysis CGM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients treat haemodialysis 3 month 1g/L glucose dialysate fluid Patients treat stable dos insulin ( regimen ) Type 2 diabetes without oral antidiabetic agent Age &gt; 18 year Noninclusion Criteria : Blood transfusion 2 previous month Life expectancy less 1 year Chronic inflammatory disease Steroid treatment &gt; 5mg/day Cancer ( evolutive require chemotherapy radiotherapy ) exception breast intraductal carcinoma operate Patient wait programmed surgery History cardiovascular disease ( stroke , coronary heart disease , hospitalization heart failure ) 4 previous month Patients suffer stage 3 4 cardiac insufficiency Noncompliant patient History pancreatitis History angioedema Hypersensitivity active substance excipients GalvusÂ®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>